Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) have earned an average rating of “Hold” from the eight analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $3.70.

Several brokerages have weighed in on FATE. Weiss Ratings reissued a “sell (e+)” rating on shares of Fate Therapeutics in a report on Wednesday, October 8th. Wedbush raised Fate Therapeutics from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $5.00 to $7.00 in a report on Monday. Wall Street Zen raised Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 18th. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a report on Monday. Finally, Wells Fargo & Company reduced their price objective on Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating for the company in a research note on Wednesday, August 13th.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Savant Capital LLC purchased a new position in shares of Fate Therapeutics in the second quarter worth about $27,000. Bridgeway Capital Management LLC purchased a new position in shares of Fate Therapeutics in the second quarter worth about $28,000. CWM LLC raised its stake in shares of Fate Therapeutics by 899.6% in the first quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 37,290 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Fate Therapeutics in the second quarter worth about $56,000. Finally, Caption Management LLC purchased a new position in shares of Fate Therapeutics in the first quarter worth about $45,000. 97.54% of the stock is currently owned by hedge funds and other institutional investors.

Fate Therapeutics Stock Performance

Shares of NASDAQ FATE opened at $1.49 on Friday. The company has a market cap of $171.84 million, a PE ratio of -1.03 and a beta of 2.34. The business has a 50-day simple moving average of $1.21 and a two-hundred day simple moving average of $1.19. Fate Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $3.50.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.06. The business had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.16 million. Fate Therapeutics had a negative return on equity of 50.95% and a negative net margin of 2,025.05%. On average, sell-side analysts predict that Fate Therapeutics will post -1.63 earnings per share for the current fiscal year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.